ES

Establishment Labs Holdings Inc.

ESTAHealthcareNASDAQ

Medical Devices · Last scanned Sep 9, 2026

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$211.1M
+27.1% YoY
Net Income
-$51.1M
+39.6% YoY
EBITDA
-$22.3M
+60.4% YoY
Free Cash Flow
-$19.3M

Scan Results

Daily timeframe
5 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Sep 3CONFIRMED Above MA150+0.6% from MA150, price crossed above
MACD Positive CrossoverHistogram +0.1562, positive momentum
Aug 27 Below MA2000.9% below MA200
About Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa,. With a market capitalization of $2.24B, it sits in mid-cap territory. The company offers silicone gel-filled breast implants under the Motiva Implants brand.

Where ESTA stands vs its 150-day and 200-day moving averages

As of the September 3, 2026 close, ESTA finished 0.58% above its 150-day moving average ($74.49) and 2.31% above its 200-day moving average ($73.23). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is ESTA overbought or oversold?

At the September 3, 2026 close, ESTA's RSI(14) was 48.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$2.24B
Fwd P/E1254.83
EPS$-1.27
Beta1.05
52W Change+95.9%
ROE-175.3%
Analysis

The company holds $71.2M in cash, though total debt stands at $263.7M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$19.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -175.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $161.7M (2022) to $211.1M (2025), reflecting a 31% increase over the period.

Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing ESTA.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms